Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
Study sponsor: Alkermes, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-09-06Actual
Enrollment · participants523Actual
Source updated2024-09-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.